c-Met modulators and method of use

21739405.1:DCC - 13/07/2021 The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines...

Full description

Saved in:
Bibliographic Details
Main Authors Huynh, Tai Phat, Takeuchi, Craig Stacy, Wang, Yong, Jammalamadaka, Vasu, Chan, Diva Sze-Ming, Leahy, James William, Parks, Jason Jevious, Dalrymple, Lisa Esther, Mann, Grace, Mann, Larry W, Xu, Wei, Chen, Jeff, Forsyth, Timothy Patrick, Nuss, John M, Bannen, Lynne Canne, Mac, Morrison B, Khoury, Richard Gregory
Format Patent
LanguageEnglish
Published 12.08.2021
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:21739405.1:DCC - 13/07/2021 The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Bibliography:Application Number: AU20210205066